Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Launches Generic Cozaar/Hyzaar With Market Exclusivity As FDA Seeks Court Action To Permit Other Entrants

Executive Summary

Teva's skirmish with FDA has paid off. The company launched generic versions of Merck's top-selling hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide) on April 6 with 180 days of marketing exclusivity
Advertisement

Related Content

New Tactic In ANDA Litigation: Novo Blocks Generic Prandin By Changing Its Patent Use Code
New Tactic In ANDA Litigation: Novo Blocks Generic Prandin By Changing Its Patent Use Code
Teva's Generic Exclusivity For Cozaar/Hyzaar Is Upheld By District Court; Apotex Appeals

Topics

Advertisement
UsernamePublicRestriction

Register

PS052122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel